While histone deacetylase (HDAC) inhibitors like Vorinostat (licensed for cutaneous T-cell lymphoma) have demonstrated efficacy, their clinical use is often limited by off-target effects, including fatigue, thrombocytopenia, and gastrointestinal toxicities188. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.